Abstract: Therapies shown to
Introduction
Bronchiectasis, defined as permanent dilatation of the airways, usually causes chronic cough and sputum production with intermittent bacterial exacerbations [Ilowite et al. 2008; O'Donnell, 2008; Barker, 2002] . Bronchiectasis can have a severe impact on quality of life for many patients due to these symptoms [Courtney et al. 2008] . Authors have lamented that, although bronchiectasis is common throughout the world, its importance has been underappreciated [Ilowite et al. 2008] and there has been little interest in the development of new treatments for the disease [Tsang and Tipoe, 2004] . This is most likely because pharmaceutical companies and device manufacturers have long perceived the bronchiectasis population as too small to make it economically profitable to develop products for this population. Indeed, despite its prevalence worldwide, bronchiectasis has been referred to an 'orphan disease' by some [O'Donnell, 2008] .
In the US, the prevalence of bronchiectasis is estimated to be over 110,000 [Weycker et al. 2005] , or approximately 1 in 3000. In other parts of the world, the prevalence is likely to be higher as the disease is more frequent in populations with poorer access to healthcare. Recently, it appears that bronchiectasis is being recognized more commonly, probably due to the more frequent use of high-resolution CT scans of the chest. Perhaps as a result of the apparent increase in prevalence in bronchiectasis, as well as the perceived unmet needs in therapy for bronchiectasis, in recent years pharmaceutical companies have become increasingly interested in developing new therapies for this disease.
There are several themes that emerge when one discusses treatments for bronchiectasis. First, most studies of therapies in bronchiectasis have suffered from methodologic flaws. Many have suffered from problems such as small numbers, lack of blinding or the use a retrospective design. This cannot be blamed on the investigators, who were no doubt aware of these issues. However, without funding, large double-blind, placebocontrolled studies are impossible, and funding for bronchiectasis studies has not been easy to obtain.
In addition, it must be remembered that bronchiectasis is not cystic fibrosis (CF). Several of the therapies to be discussed have been proven efficacious in CF in high-quality studies, but have not been as well studied in bronchiectasis. Nonetheless, these therapies have been utilized in patients with bronchiectasis by physicians and patients who are desperate to realize a potential benefit. However, bronchiectasis patients may not respond in the same way as CF patients. For example, DNase, clearly beneficial in CF, actually worsened outcomes compared with placebo in a double-blind, randomized trial [O'Donnell et al. 1998 ]. In addition, it has been difficult to determine the appropriate endpoints to study in bronchiectasis patients. While forced expiratory volume in 1 second (FEV 1 ) is a time-tested endpoint for CF, therapies for bronchiectasis rarely result in improved FEV 1 . Quality of life (QOL) may be an appropriate endpoint, but the US Food and Drug Administration (FDA) does not always accept QOL as a primary endpoint for registration trials.
With these considerations in mind, in this article we review recent developments in therapy for bronchiectasis. Several of the therapies discussed are currently available, and are increasingly being used 'off-label' for bronchiectasis. Others are currently in development and are not yet available for use.
Inhaled antibiotics
Inhaled tobramycin has been available for use in CF for over 10 years. In CF patients chronically colonized with Pseudomonas sp., the use of inhaled tobramycin results in improved lung function [Ramsey et al. 1999] . Since approximately 25% of patients with bronchiectasis are colonized with Pseudomonas aeruginosa, and these patients are generally the most severely affected [Angrill et al. 2002] , there has been great interest in this drug as a potential therapy for bronchiectasis patients. A double-blind study in which 37 stable patients with bronchiectasis and Pseudomonas were randomized to receive either placebo or inhaled tobramycin twice a day for 4 weeks was performed [Barker et al. 2000] . At the end of treatment, the treatment group had a mean 4.5 log unit decrease in Pseudomonas and 35% of patients had the organism eradicated, while the organism was eradicated in none of the placebo patients. Resistant organisms developed in four (11%) of the treated patients. A significantly higher percentage of treated patients were thought to be clinically improved at the end of treatment, compared with placebo. However, more patients in the treatment group required hospitalization (five versus one; p ¼ 0.20) and a significantly higher percentage of treated patients complained of chest pain, wheezing and dyspnea. In an open-label study of inhaled tobramycin for 12 weeks (three cycles of 2 weeks of therapy followed by 2 weeks off therapy), there was improved QOL after treatment, as measured by the St George's Respiratory Questionnaire (SGRQ) [Scheinberg and Shore, 2005] . Resistance developed in two patients. Unfortunately, about a quarter of the patients failed to complete the course of therapy due to adverse events, most commonly cough, wheeze and dyspnea related to the treatment. In another study, 30 patients were entered into crossover study in which each patient received 6 months of inhaled tobramycin and 6 months of placebo, in random order [Drobnic et al. 2005] . While neither QOL nor pulmonary physiology were improved during the treatment period, patients required fewer hospital admissions while on therapy. When inhaled tobramycin was added to oral ciprofloxacin for the treatment of exacerbations, the tobramycin did not improve clinical parameters, although the percentage of patients who achieved a microbiologic cure was increased. Once again, wheezing was a significant problem for many of the patients [Bilton et al. 2006 ].
More recently, inhaled aztreonam has been investigated as an agent for the treatment of patients with CF and bronchiectasis. When given at a dose of 75 mg two or three times a day for 28 days to patients with CF, treated patients had a significant improvement in FEV 1 , QOL and Pseudomonas density in the sputum, compared with placebo-treated patients [McCoy et al. 2008] . The MIC50 (MIC = minimal inhibitory concentration) and MIC90 of the Pseudomonas isolates did not increase after exposure to aztreonam, although there was an increase in the proportion of isolates with an MIC over 8 mg/ml (the breakpoint for parenteral treatment). On the basis of these data, as well as unpublished data, FDA recently approved inhaled aztreonam for use in patients with CF. A phase II study of this therapy in patients with bronchiectasis recently completed enrollment, but results are not yet available.
Two companies are in the process of developing formulations of ciprofloxacin for use in CF and bronchiectasis. Aradigm is developing liposomal Therapeutic Advances in Respiratory Disease 4 (2) ciprofloxacin, which allows a slow release of the drug, facilitating once-daily treatment. They recently reported interim results of their phase II study of liposomal ciprofloxacin, in which 36 patients received once daily treatment for 28 days [Bilton et al. 2009a [Bilton et al. , 2009b . They demonstrated an approximately 4 log decrease in the density of Pseudomonas in the sputum. Data on pulmonary function and QOL have not yet been reported. Bayer is also developing a nebulized ciprofloxacin product and is currently enrolling patients in a phase II randomized, placebo-controlled study in which the treatment arm will receive twice-a-day treatment for 28 days. For both of these products, in addition to efficacy, the frequency at which resistant organisms are isolated will be a critical outcome. While the selection for organisms resistant to tobramycin or aztreonam leaves several other options for intravenous therapy directed at Pseudomonas species, the development of fluoroquinolone-resistant Pseudomonas generally leaves no options for oral therapy. Of course this risk will ultimately be balanced against the risk of developing fluoroquinolone resistance due to repetitive courses of oral fluoroquinolones to treat exacerbations.
Nebulized colistin has been used in patients with CF for many years. There was a recent retrospective study of 18 patients with chronic Pseudomonas or Stenotrophomonas bronchial sepsis (14 with bronchiectasis) who had been receiving a regimen of nebulized colistin, 30 mg a day for between 6 and 116 months. No complications were reported and a lower rate of decline of FEV 1 and forced vital capacity (FVC) was seen after commencement of therapy. The frequency of hospital admissions did not decline with treatment, but the study was underpowered for this endpoint. Patients reported improved QOL on therapy, but this was based on retrospective recall, so must be viewed with caution [Steinfort and Steinfort, 2007] .
Other agents are also being investigated for potential use in bronchiectasis. Preliminary results of a phase II study of nebulized liposomal amikacin have been reported, with no safety concerns noted during an interim analysis [O'Donnell et al. 2009 ]. In-vitro and animal studies using intratracheal instillation of a fosfomycin/tobramycin combination demonstrated reasonable activity against a variety of pathogens, although there was poor activity against Burkholderia cepacia and S. maltophilia [MacLeod et al. 2009 ].
Hyperosmolar agents
Inhalation of hyperosmolar agents may benefit patients with mucus retention by drawing water into the airways, thus changing the rheology of the mucus, and allowing more rapid and effective clearance. Two studies of 7% saline solution in CF patients demonstrated benefits including improved pulmonary function and a reduction in exacerbations [Donaldson et al. 2006; Elkins et al. 2006] . There are only limited data regarding hypertonic saline in bronchiectasis. In one study, 24 patients with bronchiectasis received each of 4 treatments on 4 separate days: active cycle breathing (ACB) alone, nebulized terbutaline followed by ACB, nebulized terbutaline, followed by normal saline, then ACB and nebulized terbutaline, followed by 7% saline, then ACB [Kellett et al. 2005] . Patients produced more sputum and rated the ease of expectoration easiest after receiving the 7% saline treatment. There is currently a long-term study of 6% saline in bronchiectasis which is still enrolling patients.
Inhaled dry powder mannitol is also being developed as a potential treatment for both CF and bronchiectasis. Mannitol has the theoretical advantage that its halflife in the airways is much longer than that of hypertonic saline, allowing for the potential of a more sustained effect. Approximately 1525% of patients with bronchiectasis will have bronchial hyperresponsiveness after inhalation of mannitol, depending on the dose, limiting the number of bronchiectasis patients who could potentially be treated.
In a 'proof of concept' study, bronchiectasis patients inhaled a single dose of inhaled mannitol [Daviskas et al. 1999] . Mucus clearance during the following 75 minutes, as measured by the clearance of (99m) Tc-sulfur colloid radioaerosol was increased over the baseline and placebo. In a subsequent study, increased clearance during the 24 hours after a single dose of mannitol was seen after inhalation. This increased clearance was evident within 2 hours of the inhalation of the mannitol, but was no longer evident after 24 hours [Daviskas et al. 2001] . The same group subsequently measured the effect of 12 days of treatment with inhaled dry powder mannitol on lung function, QOL and sputum properties. Quality of life, as assessed by the SGRQ, improved significantly by day 12, although it must be remembered that this was an uncontrolled, unblinded study. Pulmonary function was largely unchanged, although a significant improvement in forced expiratory flow rate was seen. Some of the characteristics of the patient's sputum did improve, including the solid content, which dropped, consistent with mannitol drawing water into the airway. Cough transportability also increased with treatment [Daviskas et al. 2005] .
Based on these promising preliminary data, a large multicenter, placebo-controlled trial of inhaled mannitol in patients with bronchiectasis was performed and reported in abstract form at the 2009 American Thoracic Society meeting [Bilton et al. 2009a [Bilton et al. , 2009b . Patients received either 320 mg of mannitol twice a day n ¼ 185, or placebo twice a day (n ¼ 95) for 3 months. Statistically significant improvements in total SGRQ scores were seen in the treatment group, relative to placebo group (3.9 versus 2.0; p < 0.04). In addition, the time to antibiotic use was longer in the treatment group (p ¼ 0.045) and the percentage of patients who required antibiotics was lower in the patients who received mannitol (16% versus 27%; p ¼ 0.03).
Taken together, the studies of mannitol and hypertonic saline suggest that these agents may eventually be shown to benefit patients with bronchiectasis. A recent review and a systematic review in the Cochrane database were in agreement that there was not enough data yet to recommend either of these treatments as routine therapy for patients with bronchiectasis [Ilowite et al. 2008; Wills and Greenstone, 2001 ].
Anti-inflammatory agents
Corticosteroids, given by either inhaled or systemic route, have long been used in bronchiectasis and inhaled corticosteroids appear to have marginal benefit when used chronically. Systemic corticosteroids are often given to patients with acute exacerbations when airway hyperreactivity is present. Given the lack of new data, corticosteroids will not be discussed further in this article.
Macrolide antibiotics have immunomodulatory effects in vitro and in vivo that are distinct from their antibacterial properties. These effects were first demonstrated to be clinically significant in diffuse panbronchiolitis, a disease seen in older Asian men characterized by chronic cough and sputum production, chronic Pseudomonas airway suppuration and a substantial mortality rate. Treatment with macrolide antibiotics results in decreased sputum volume and improved 5-year mortality in these patients [Kudoh et al. 1998 ]. Several potential mechanisms may be responsible for these benefits. Macrolides may decrease sputum production by directly affecting chloride diffusion. In addition, macrolides have a wide variety of immunomodulatory effects in vitro that might attenuate the chronic airway inflammation seen in diffuse panbronchiolitis and other suppurative airway diseases, such as bronchiectasis. Some of these effects include inhibition of inflammatory cell migration, inhibition of cytokine secretion and decreasing the production of reactive oxygen species. Although macrolides are not active against Pseudomonas sp., they do inhibit the organism's ability to produce a protective biofilm, produce toxins as well as other important functions [Shinkai et al. 2008] .
Several studies have investigated clinical and microbiologic effects of macrolide antibiotics in patients with bronchiectasis. A retrospective review of the experience in 56 patients who were prescribed azithromycin at a dose of 250 mg three times a week if they had suffered from three or more exacerbations in a 6-month period was recently published [Anwar et al. 2008] . After beginning azithromycin, patients had a 50% decrease in the frequency of exacerbations (0.810.41 per month), a decrease in sputum volume, sputum bacterial growth and the percentage and minor improvement in pulmonary function. Of note, the majority of the patients were colonized with organisms such as Hemophilus influenzae and Streptococcus pneumoniae, organisms which are likely to be killed by macrolides, as opposed to Pseudomonas sp. In another study, 33 patients who had at least four exacerbations during the preceding year were treated with azithromycin at a dose of 500 mg three times a week for at least 4 months [Davies and Wilson, 2004] . Patient reported symptoms including sputum volume, cough and fatigue all improved to a statistically significant degree. Although both of these studies are encouraging, they were unblinded and uncontrolled.
A randomized study of clarithromycin has been performed in 34 children with non-CF bronchiectasis. Subjects received either clarithromycin at a dose of 15 mg/kg a day or standard therapy, in an unblinded fashion [Yalcin et al. 2006] . A statistically significant decrease in sputum volume after 3 months was seen in treatment group only, although the actual changes in sputum volume not given. No significant change in pulmonary function test parameters for treatment versus control was seen. Bronchoalveolar lavage total cell count, neutrophil ratios and interleukin-8 (IL-8) decreased in the treatment group only, while there was no change in other bronchoalveolar lavage (BAL) inflammatory markers such as tumor necrosis factor (TNF) and IL-10, nor in pulmonary function. In a randomized, double-blind study of erythromycin, 500 mg twice a day for 6 weeks in 21 adult patients with bronchiectasis [Tsang et al. 1999] patients receiving active treatment demonstrated an improvement in FEV 1 (0.14 L) and FVC (0.12 L), both of which were statistically significant, while there was no change in physiology in patients receiving placebo. Patients on erythromycin also had a significant decrease in 24-hour sputum volume of 10 ml (p < 0.05), while patients receiving placebo decreased by only 3.5 ml. Surprisingly, erythromycin treatment did not result in improvements in sputum bacterial density or the concentration of several inflammatory mediators.
In summary, while many of the studies suffer from significant methodologic problems, there is some evidence that low-dose macrolide treatment provides benefit to patients with bronchiectasis and chronic mucus hypersecretion. While many physicians are using macrolides in these patients, there is not enough evidence to state that all such patients should be on macrolide therapy. Since there is limited evidence of improved outcomes, the author's own practice is to try macrolide treatment on selected patients for a 36-month period and discontinue therapy if there is no perceived benefit for the patient in terms of QOL or frequency of exacerbations. There is one important note of caution regarding the risk of macrolide therapy in patients who may have concomitant Mycobacterium avium (MAC) infection or colonization. Macrolide monotherapy in such patients increases the likelihood of selection for macrolide-resistant MAC. Macrolide-resistant MAC is very difficult to treat and has a high likelihood of treatment failure [Griffith et al. 2007] . Thus, the presence of MAC should be ruled out with at least two good-quality sputum samples before considering chronic macrolide therapy. In a patient who has nodular bronchiectasis suggesting MAC, even if sputum samples are negative, bronchoscopic sampling for mycobacteria should be considered before beginning macrolide therapy.
Erdosteine is a thiol derivative agent approved for use in chronic obstructive pulmonary disease in some European countries. Evidence suggests that it decreases cough and sputum due to anti-inflammatory properties related to its antioxidant activity. It was studied recently in a 15-day, open-label, randomized study of 30 bronchiectasis patients with hypersecretion in which patients received erdosteine 225 mg orally twice a day and chest physiotherapy or chest physiotherapy alone [Crisafulli et al. 2007] . Both groups reported similar improvements in symptoms in cough and dyspnea. However, only patients in the treatment group demonstrated improvements in FEV 1 and FVC. While these results are promising, further data are required before erdosteine can be recommended for the treatment of patients with bronchiectasis.
Summary
Several promising classes of therapeutic agents are being studied for the treatment of bronchiectasis. Inhaled antibiotics, including aztreonam and two formulations of ciprofloxacin are in various stages of development by pharmaceutical companies. Hypertonic saline is being used by many physicians based on its observed benefit in CF, but there are limited data in bronchiectasis patients. Inhaled mannitol is currently being investigated in a phase III trial, based on promising phase II results. Chronic therapy with low-dose macrolides is being commonly used for patients with bronchiectasis, based on a series of small, mostly unblinded studies. Prospective, randomized, double-blind data are needed before macrolides can be recommended as standard therapy.
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